View Older Stories View More Recent Stories

Dec 15, 2021 08:00AM Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Nov 22, 2021 05:38AM Exelixis (EXEL) Reports Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor
Nov 20, 2021 06:00AM Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Nov 9, 2021 08:00AM Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Can
Nov 3, 2021 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
Nov 2, 2021 04:05PM Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Oct 19, 2021 04:05PM Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
Oct 14, 2021 08:30AM Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Oct 14, 2021 08:04AM Exelixis (EXEL), STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Oct 14, 2021 08:00AM Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
Oct 14, 2021 08:00AM Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Sep 20, 2021 11:30AM Exelixis (EXEL) Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at
Sep 20, 2021 11:30AM Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO
Sep 18, 2021 07:30AM Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
Sep 17, 2021 04:24PM UPDATE: FDA Approves Exelixis's (EXEL) CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Sep 17, 2021 04:23PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Sep 16, 2021 02:30AM Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on Chec
Sep 6, 2021 01:00PM Exelixis Statement on the Passing of Two Senior Executives
Sep 1, 2021 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
Aug 25, 2021 04:05PM Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell C
Aug 16, 2021 08:05AM Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
Aug 5, 2021 04:05PM Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 08:01AM Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Aug 5, 2021 08:00AM Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen
Jul 22, 2021 04:05PM Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Jul 8, 2021 04:05PM Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
Jun 28, 2021 06:17AM Exelixis (EXEL) and Ipsen Report Mixed Results with Cabozantinib in Combination with Immune Checkpoint Inhibitor in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Live
Jun 28, 2021 01:00AM Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
Jun 28, 2021 01:00AM Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
Jun 18, 2021 08:01AM Exelixis (EXEL) Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
Jun 18, 2021 08:00AM Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
Jun 14, 2021 08:01AM Exelixis (EXEL) Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY) to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Jun 14, 2021 08:00AM Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Jun 7, 2021 08:04AM Exelixis (EXEL), Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer P
Jun 7, 2021 08:00AM Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
Jun 7, 2021 08:00AM Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
Jun 4, 2021 09:01AM Exelixis (EXEL) Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX in Combination with OPDIVO as First-line Treatment for Patients with Advanced RCC
Jun 4, 2021 09:00AM Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Pr
Jun 4, 2021 09:00AM Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
Jun 4, 2021 09:00AM Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Pa
May 26, 2021 04:15PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
May 24, 2021 04:09PM Exelixis (EXEL) Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
May 24, 2021 04:05PM Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
May 6, 2021 04:05PM Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 4, 2021 08:07AM Exelixis (EXEL) Announces Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
May 4, 2021 08:00AM Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
Apr 29, 2021 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Apr 27, 2021 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
Apr 22, 2021 04:05PM Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
Apr 5, 2021 08:01AM Exelixis (EXEL) Announces U.S. FDA Accepts IND Application for XB002 in Patients with Advanced Solid Tumors
View More Recent Stories View Older Stories